Breaking News

Almac Discovery Selects Preclinical Cancer Candidate

December 18, 2012

Seeks development and commercialization partner

Almac Discovery has selected a preclinical development candidate from its allosteric Akt inhibitor program. Akt, a component of the PI3K pathway, is associated with driving tumor growth in many cancer types. ALM301, a potent, subtype selective Akt1 & Akt2 inhibitor, has demonstrated efficacy in prostate, breast and other cancer models, both as a single agent and in combination with other chemotherapeutic agents.
 
Effects on tumor growth inhibition in these studies also correlate with Akt pathway biomarkers. Preclinical development activities are scheduled to start early in 2013. Almac Discovery is currently seeking partners for the continued development and commercialization of ALM301 on a global basis.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent